| Autor: |
Piccinelli E; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.; Department of Mechanical and Aerospace Engineering, Politecnico di Torino, 10129 Torino, Italy., Grutter G; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Pilati M; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Rebonato M; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Scalera ST; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Adorisio R; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Amodeo A; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Ingrasciotta G; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Mencarelli E; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Galletti L; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy., Butera G; Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy. |
| Abstrakt: |
The CardioMEMS HF System (Abbott, Abbott Park, IL) is the first FDA- and CE-Mark-approved device for monitoring patients with heart failure, significantly reducing hospitalizations and improving the quality of life for NYHA class III non-congenital adult patients. This device, implanted percutaneously, allows the direct monitoring of pulmonary arterial pressure with the wireless transfer of pressure data to the clinician, who can adjust the therapy remotely. Limited experience exists regarding its use in patients with congenital heart disease (CHD). CardioMEMS device implantation is feasible and safe in selected adults and children with CHD. The potential of the device to reduce heart failure hospitalizations in this population is enormous, but further multi-center studies are needed to demonstrate its efficacy. |
